ATRX is altered in 5.56% of gliosarcoma patients [2].

ATRX is an inclusion eligibility criterion in 1 clinical trial for gliosarcoma, of which 0 are open and 1 is closed. Of the trial that contains ATRX status and gliosarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

EGFR is altered in 14.71% of gliosarcoma patients [2].

EGFR is an inclusion eligibility criterion in 3 clinical trials for gliosarcoma, of which 2 are open and 1 is closed. Of the trials that contain EGFR status and gliosarcoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for gliosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and gliosarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

H3F3A is an inclusion eligibility criterion in 2 clinical trials for gliosarcoma, of which 2 are open and 0 are closed. Of the trials that contain H3F3A status and gliosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MET is altered in 1.49% of gliosarcoma patients [2].

MET is an inclusion eligibility criterion in 1 clinical trial for gliosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and gliosarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TERT is altered in 1.96% of gliosarcoma patients [2].

TERT is an inclusion eligibility criterion in 1 clinical trial for gliosarcoma, of which 1 is open and 0 are closed. Of the trial that contains TERT status and gliosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TP53 is altered in 52.94% of gliosarcoma patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for gliosarcoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and gliosarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].